JP2007533686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533686A5 JP2007533686A5 JP2007508810A JP2007508810A JP2007533686A5 JP 2007533686 A5 JP2007533686 A5 JP 2007533686A5 JP 2007508810 A JP2007508810 A JP 2007508810A JP 2007508810 A JP2007508810 A JP 2007508810A JP 2007533686 A5 JP2007533686 A5 JP 2007533686A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- agonist
- active ingredient
- dopamine
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 31
- 239000004480 active ingredient Substances 0.000 claims 18
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 16
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 16
- 239000005557 antagonist Substances 0.000 claims 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 16
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 16
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 16
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 13
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims 13
- 229960002053 flibanserin Drugs 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 8
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims 8
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 8
- 239000000674 adrenergic antagonist Substances 0.000 claims 8
- 229960000711 alprostadil Drugs 0.000 claims 8
- 239000003098 androgen Substances 0.000 claims 8
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 229960003638 dopamine Drugs 0.000 claims 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 8
- 239000000262 estrogen Substances 0.000 claims 8
- 229940011871 estrogen Drugs 0.000 claims 8
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 8
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 7
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 7
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000003287 optical effect Effects 0.000 claims 6
- 230000001568 sexual effect Effects 0.000 claims 6
- 108010008364 Melanocortins Proteins 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000002865 melanocortin Substances 0.000 claims 5
- 239000003723 serotonin 1A agonist Substances 0.000 claims 5
- 102000001307 androgen receptors Human genes 0.000 claims 4
- 108010080146 androgen receptors Proteins 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 239000000336 melanocortin receptor agonist Substances 0.000 claims 3
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 2
- 208000029899 Sexual aversion disease Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000024309 orgasm disease Diseases 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 230000035946 sexual desire Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56466204P | 2004-04-22 | 2004-04-22 | |
| US63180004P | 2004-11-30 | 2004-11-30 | |
| PCT/EP2005/004081 WO2005102342A1 (en) | 2004-04-22 | 2005-04-18 | New pharmaceutical compositions for the treatment of sexual disorders ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533686A JP2007533686A (ja) | 2007-11-22 |
| JP2007533686A5 true JP2007533686A5 (enExample) | 2008-06-05 |
Family
ID=34966041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508810A Pending JP2007533686A (ja) | 2004-04-22 | 2005-04-18 | 性的障害ｉｉ治療用の新規医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20050245539A1 (enExample) |
| EP (1) | EP1740181A1 (enExample) |
| JP (1) | JP2007533686A (enExample) |
| KR (1) | KR20070014184A (enExample) |
| AR (1) | AR048705A1 (enExample) |
| AU (1) | AU2005235422B2 (enExample) |
| BR (1) | BRPI0510074A (enExample) |
| CA (1) | CA2563743A1 (enExample) |
| IL (1) | IL178730A0 (enExample) |
| MX (1) | MXPA06012059A (enExample) |
| NZ (1) | NZ551340A (enExample) |
| PE (1) | PE20060464A1 (enExample) |
| RU (1) | RU2445095C2 (enExample) |
| TW (1) | TW200538115A (enExample) |
| UY (1) | UY28862A1 (enExample) |
| WO (1) | WO2005102342A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862445B2 (en) * | 1995-10-06 | 2017-03-22 | Arch Development Corporation | Combination of herpes simplex virus and chemotherapy for treating cancer |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| CN101027061B (zh) | 2004-05-11 | 2014-03-12 | 情感智能有限责任公司 | 药物制剂及其在治疗女性性功能障碍中的应用 |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| EP1789048A1 (en) * | 2004-09-03 | 2007-05-30 | Boehringer Ingelheim International GmbH | Method for the treatment of attention deficit hyperactivity disorder |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| EP1858514B1 (en) * | 2005-03-17 | 2014-11-26 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
| JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| CA2617546C (en) | 2005-08-03 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| US20070142395A1 (en) * | 2005-12-16 | 2007-06-21 | Vela Pharmaceuticals, Inc. | Treatment of sexual dysfunction with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof |
| US20090023712A1 (en) * | 2006-02-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin |
| US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| BRPI0712039A2 (pt) * | 2006-05-09 | 2011-12-20 | Boehringer Ingelheim Int | uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| CA2652300A1 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
| KR20090029237A (ko) | 2006-06-02 | 2009-03-20 | 피어 트리 파머슈티칼스 인코포레이티드 | 위축성 질염을 치료하는 방법 |
| WO2008000760A1 (en) * | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| US20090239881A1 (en) * | 2006-07-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| EP1880714A1 (en) * | 2006-07-20 | 2008-01-23 | Helm AG | Amorphous Aripiprazole and Process for the Preparation thereof |
| CA2660476C (en) | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| WO2008022932A2 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2097389B1 (en) * | 2006-12-20 | 2011-09-14 | Boehringer Ingelheim International GmbH | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| US8304601B2 (en) * | 2007-01-23 | 2012-11-06 | Keiko Fujikawa | Mouse model for eye disease |
| EP2114384A4 (en) * | 2007-02-15 | 2012-02-01 | Derma Young Ltd | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCTIVE ADMINISTRATION |
| CA2682015A1 (en) * | 2007-03-28 | 2008-10-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
| TW200918542A (en) * | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| PE20091188A1 (es) * | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| US20110028480A1 (en) * | 2008-04-01 | 2011-02-03 | Ocean 1 806, Llc | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors |
| US20090281114A1 (en) * | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| EA201391459A1 (ru) * | 2011-04-04 | 2014-03-31 | С1 Биофарма, Инк. | Режимы лечения |
| JO3421B1 (ar) * | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| US9517254B2 (en) * | 2012-08-06 | 2016-12-13 | S1 Biopharma, Inc. | Treatment regimens |
| EP3071207A4 (en) * | 2013-11-20 | 2017-08-16 | Scott Freeman Consultant, LLC | Libido-enhancing therapeutic and use |
| CN105859573B (zh) * | 2015-01-21 | 2018-02-09 | 上海右手医药科技开发有限公司 | 一种阿戈美拉汀硫酸复合物多晶型b及其制备方法和应用 |
| ES2865254T3 (es) * | 2015-06-01 | 2021-10-15 | Durga Entpr Llc | Composiciones para el tratamiento de la vaginitis atrófica, dispareunia perimenopáusica y posmenopaúsica y/o mujeres ooforectomizadas y métodos de tratamiento con las mismas |
| KR20170142797A (ko) * | 2016-06-17 | 2017-12-28 | 에스원 바이오파머, 인크. | 부프로피온 및 트라조돈 조합 치료를 이용한 여성의 성욕 감퇴 장애（ｈｓｄｄ）의 치료 방법 |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| WO2018129461A1 (en) * | 2017-01-08 | 2018-07-12 | Olive Therapeutics, LLC | Treatment of sexual dysfunction |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| CN118806732A (zh) | 2018-06-20 | 2024-10-22 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12419890B2 (en) * | 2019-02-27 | 2025-09-23 | Takeda Pharmaceutical Company Limited | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
| CA3169745A1 (en) * | 2020-04-07 | 2021-10-14 | Inversago Pharma Inc. | Process for producing 4,5-dihydro-1h-pyrazoles and intermediates |
| WO2023107931A1 (en) * | 2021-12-06 | 2023-06-15 | Terran Biosciences, Inc. | Salt and solid forms of indole analogs and methods of use thereof |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| KR20250100660A (ko) | 2022-10-25 | 2025-07-03 | 베라더믹스 인코포레이티드 | 변형 방출 미녹시딜의 조성물 및 사용 방법 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
| US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
| US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
| IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| NL8601494A (nl) * | 1985-06-22 | 1987-01-16 | Sandoz Ag | Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten. |
| GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
| US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
| NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
| US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
| US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
| US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
| PL337813A1 (en) * | 1997-06-11 | 2000-09-11 | Procter & Gamble | Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| JP3584845B2 (ja) * | 2000-03-16 | 2004-11-04 | 日立ハイテク電子エンジニアリング株式会社 | Ｉｃデバイスの試験装置及び試験方法 |
| US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| EP1256343B1 (en) * | 2001-05-11 | 2006-07-05 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
| WO2003007949A1 (en) * | 2001-07-18 | 2003-01-30 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| EP1551393A4 (en) * | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| US20050004105A1 (en) * | 2003-01-29 | 2005-01-06 | Emer Leahy | Treatment for a attention-deficit hyperactivity disorder |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| JP2007516949A (ja) * | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
| US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CA2660476C (en) * | 2006-08-14 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
-
2005
- 2005-04-18 KR KR1020067024443A patent/KR20070014184A/ko not_active Ceased
- 2005-04-18 RU RU2006140962/15A patent/RU2445095C2/ru not_active IP Right Cessation
- 2005-04-18 EP EP05736586A patent/EP1740181A1/en not_active Ceased
- 2005-04-18 JP JP2007508810A patent/JP2007533686A/ja active Pending
- 2005-04-18 AU AU2005235422A patent/AU2005235422B2/en not_active Ceased
- 2005-04-18 MX MXPA06012059A patent/MXPA06012059A/es not_active Application Discontinuation
- 2005-04-18 BR BRPI0510074-7A patent/BRPI0510074A/pt not_active IP Right Cessation
- 2005-04-18 WO PCT/EP2005/004081 patent/WO2005102342A1/en not_active Ceased
- 2005-04-18 NZ NZ551340A patent/NZ551340A/en not_active IP Right Cessation
- 2005-04-18 CA CA002563743A patent/CA2563743A1/en not_active Abandoned
- 2005-04-19 UY UY28862A patent/UY28862A1/es not_active Application Discontinuation
- 2005-04-20 US US11/110,449 patent/US20050245539A1/en not_active Abandoned
- 2005-04-20 PE PE2005000435A patent/PE20060464A1/es not_active Application Discontinuation
- 2005-04-21 TW TW094112651A patent/TW200538115A/zh unknown
- 2005-04-22 AR ARP050101598A patent/AR048705A1/es not_active Application Discontinuation
-
2006
- 2006-10-19 IL IL178730A patent/IL178730A0/en unknown
-
2007
- 2007-12-20 US US11/960,957 patent/US20080103155A1/en not_active Abandoned
-
2011
- 2011-01-10 US US12/987,388 patent/US20110105519A1/en not_active Abandoned
-
2012
- 2012-10-18 US US13/654,674 patent/US20130203766A1/en not_active Abandoned
-
2015
- 2015-03-13 US US14/656,877 patent/US20150320739A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8476259B2 (en) | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension | |
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| US20180235931A1 (en) | Use of neurokinin-1 antagonists as antitussives | |
| JP2009541443A5 (enExample) | ||
| JP2021080276A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2013544850A5 (enExample) | ||
| JP2005512995A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| EP1858516A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of depression | |
| JP2023517532A5 (enExample) | ||
| JP2009543767A (ja) | フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用 | |
| JP2019536812A5 (enExample) | ||
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| BR112021006889A2 (pt) | método para tratar prurido em um mamífero | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| EP3829572A1 (en) | Use of neurokinin-1 antagonists to treat chronic pruritus | |
| WO2009142589A1 (en) | Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP2020533402A5 (enExample) | ||
| BG65472B1 (bg) | Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство | |
| ES2358931T3 (es) | Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos. | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы |